Cancer Drug Resistance
All Journals
Search
Log In
Editor-in-Chief:
Godefridus J. Peters
Indexing:
ESCI
,
PMC
,
Scopus
,
CAS
,
CNKI
,
Dimensions
,
Lens
,
Embase
,
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Journal Flyer
Hot Keywords
Resistance
Drug delivery
Nanomedicine
Tumor microenvironment
Immune checkpoint inhibitors
Target therapy
Immunotherapy
Radiotherapy
Ferroptosis
PARP inhibitors
MYC
ABC transporters
Autophagy
Metabolism
Mechanisms
Precision medicine
Extracellular vesicles
Stem cell
Biomarker
Ovarian cancer
Renal cell carcinoma
Prostate cancer
Breast cancer
Colorectal cancer
Myeloid leukemia
Non-small cell lung cancer
Pancreatic cancer
Head and neck cancer
Squamous cell carcinoma
Mitochondria
Home
About
About the Journal
Aims and Scope
Editorial Policies
Editorial Board
Junior Editorial Board
News
Journal History
Partners
Advertise
Contact Us
Publish with us
For Authors
Author Instructions
Article Processing Charges
Editorial Process
Manuscript Templates
Submit a Manuscript
For Reviewers
Peer Review Guidelines
Articles
All Articles
Articles with Video Abstracts
Video Abstract Guidelines
Articles Ebooks
Special Issues
All Special Issues
Ongoing Special Issues
Special Issue Ebooks
Special Issue Guidelines
Special Collections
Volumes
Pre-onlines
Features
Webinars
Academic Talks
Interviews
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Cancer Drug Resistance
Search
Submit
Editor-in-Chief:
Godefridus J. Peters
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Home
Volumes
Volume4
Volume4, Issue2 (2021)
Volume
Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy
Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
Curcumin: reclaiming the lost ground against cancer resistance
Regulation of cancer stem cells in triple negative breast cancer
Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer
Statins and endocrine resistance in breast cancer
The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance
Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response
DNA direct reversal repair and alkylating agent drug resistance
Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications
Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy
ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome
UCP2 - Taking the heat out of P-glycoprotein?
Overcoming drug resistance in glioblastoma: new options in sight?
Actions for 0 selected articles
Download PDFs >
Cancer Drug Resistance
ISSN 2578-532X (Online)
editorial@cdrjournal.com
Navigation
Contact Us
Sitemap
Follow Us
LinkedIn
Twitter
WeChat
Navigation
Contact Us
Sitemap
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/